BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 15909492)

  • 1. Correlation between serum CEA level and metabolic volume as determined by FDG PET in postoperative patients with recurrent colorectal cancer.
    Choi MY; Lee KM; Chung JK; Lee DS; Jeong JM; Park JG; Kim JH; Lee MC
    Ann Nucl Med; 2005 Apr; 19(2):123-9. PubMed ID: 15909492
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of CT, FDG PET-CT and serum tumor markers in staging recurrent colorectal cancer.
    Caglar M; Yener C; Karabulut E
    Int J Comput Assist Radiol Surg; 2015 Jul; 10(7):993-1002. PubMed ID: 25213271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical impact of 18F-FDG-PET in the suspicion of recurrent colorectal cancer based on asymptomatically elevated serum level of carcinoembryonic antigen (CEA) in Taiwan.
    Shen YY; Liang JA; Chen YK; Tsai CY; Kao CH
    Hepatogastroenterology; 2006; 53(69):348-50. PubMed ID: 16795969
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of 18F-FDG PET/CT in detecting colorectal cancer recurrence in patients with elevated CEA levels.
    Ozkan E; Soydal C; Araz M; Kir KM; Ibis E
    Nucl Med Commun; 2012 Apr; 33(4):395-402. PubMed ID: 22367859
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer.
    Huang YY; Lee PI; Liu MC; Chen CC; Huang KC; Huang AT
    Clin Nucl Med; 2015 Oct; 40(10):e465-9. PubMed ID: 26204213
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Evaluation of positron emission tomography by using F-18-fluorodeoxyglucose in diagnosis of recurrent colorectal cancer].
    Kula Z; Szefer J; Zuchora Z; Romanowicz G; Pietrzak T
    Pol Merkur Lekarski; 2004; 17 Suppl 1():63-6. PubMed ID: 15603351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective study on diagnostic and prognostic significance of postoperative FDG PET/CT in recurrent colorectal carcinoma patients: comparison with MRI and tumor markers.
    Odalovic S; Stojiljkovic M; Sobic-Saranovic D; Pandurevic S; Brajkovic L; Milosevic I; Grozdic-Milojevic I; Artiko V
    Neoplasma; 2017; 64(6):954-961. PubMed ID: 28895416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Performance of FDG PET/CT in postoperative colorectal cancer patients with a suspected recurrence and a normal CEA level.
    Lee JH; Park SG; Jee KN; Park DG; Namgung H; Song IH
    Nucl Med Commun; 2010 Jun; 31(6):576-82. PubMed ID: 20216474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [¹⁸F-FDG PET/CT. Its correlation with carcinoembryonic antigen in patients with colorectal carcinoma].
    Granados Rangel O; Estrada G; Altamirano J
    Gac Med Mex; 2014; 150(6):509-17. PubMed ID: 25375281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The utility of FDG-PET/CT as an effective tool for detecting recurrent colorectal cancer regardless of serum CEA levels.
    Sanli Y; Kuyumcu S; Ozkan ZG; Kilic L; Balik E; Turkmen C; Has D; Isik G; Asoglu O; Kapran Y; Adalet I
    Ann Nucl Med; 2012 Aug; 26(7):551-8. PubMed ID: 22644560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PET and PET-CT for evaluation of colorectal carcinoma.
    Delbeke D; Martin WH
    Semin Nucl Med; 2004 Jul; 34(3):209-23. PubMed ID: 15202102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of resectable recurrences in colorectal cancer patients with 2-[18F]fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography.
    Peng NJ; Hu C; King TM; Chiu YL; Wang JH; Liu RS
    Cancer Biother Radiopharm; 2013; 28(6):479-87. PubMed ID: 23713869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 18F-FDG PET/CT superior to serum CEA in detection of colorectal cancer and its recurrence.
    Makis W; Kurzencwyg D; Hickeson M
    Clin Imaging; 2013; 37(6):1094-7. PubMed ID: 23993799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ability of 18F-FDG PET/CT to diagnose recurrent colorectal cancer in patients with elevated CEA concentrations.
    Kyoto Y; Momose M; Kondo C; Itabashi M; Kameoka S; Kusakabe K
    Ann Nucl Med; 2010 Jun; 24(5):395-401. PubMed ID: 20364373
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carcinoembryonic antigen directed PET-CECT scanning for postoperative surveillance of colorectal cancer.
    Vallam KC; Guruchannabasavaiah B; Agrawal A; Rangarajan V; Ostwal V; Engineer R; Saklani A
    Colorectal Dis; 2017 Oct; 19(10):907-911. PubMed ID: 28444968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnostic accuracy of FDG PET imaging for the detection of recurrent or metastatic gynecologic cancer.
    Khan N; Oriuchi N; Yoshizaki A; Kanuma T; Higuchi T; Endo K
    Ann Nucl Med; 2005 Apr; 19(2):137-45. PubMed ID: 15909494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Does CEA and CA 19-9 combined increase the likelihood of 18F-FDG in detecting recurrence in colorectal patients with negative CeCT?
    Panagiotidis E; Datseris IE; Rondogianni P; Vlontzou E; Skilakaki M; Exarhos D; Bamias A
    Nucl Med Commun; 2014 Jun; 35(6):598-605. PubMed ID: 24681767
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early diagnosis of recurrent breast cancer with FDG-PET in patients with progressive elevation of serum tumor markers.
    Suárez M; Pérez-Castejón MJ; Jiménez A; Domper M; Ruiz G; Montz R; Carreras JL
    Q J Nucl Med; 2002 Jun; 46(2):113-21. PubMed ID: 12114874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diagnostic value of (18)F-FDG PET/CT as first choice in the detection of recurrent colorectal cancer due to rising CEA.
    Gade M; Kubik M; Fisker RV; Thorlacius-Ussing O; Petersen LJ
    Cancer Imaging; 2015 Aug; 15(1):11. PubMed ID: 26263901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.